Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TSPO | P30536 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172097 | 0.87 | ALDH1A1 (0.55) | ALDH1A1LMNATSPONPC1RAB9A | |
| SCHEMBL13472619 | 0.86 | ALDH1A1 (0.54) | ALDH1A1LMNATSPONPC1RAB9A | |
| SCHEMBL16330550 | 0.86 | ALDH1A1 (0.54) | ALDH1A1LMNATSPONPC1RAB9A | |
| SCHEMBL20009173 | 0.84 | ALDH1A1 (0.53) | ALDH1A1LMNATSPONPC1RAB9A | |
| SCHEMBL20671852 | 0.84 | ALDH1A1 (0.53) | ALDH1A1LMNATSPONPC1RAB9A | |
| SCHEMBL14224515 | 0.84 | HDAC1 (0.58) | ALDH1A1LMNATSPONPC1OPRM1 | |
| SCHEMBL4160271 | 0.84 | REN (0.54) | ALDH1A1LMNATSPONPC1TRPM8 | |
| SCHEMBL2720763 | 0.84 | LMNA (0.59) | ALDH1A1LMNATSPONPC1RAB9A | |
| SCHEMBL3213534 | 0.83 | ALDH1A1 (0.55) | ALDH1A1LMNATSPONPC1TRPM8 | |
| SCHEMBL18928159 | 0.83 | ALDH1A1 (0.51) | ALDH1A1LMNATSPONPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023018471-A9 | PIPERAZINE-BASED AGONISTS OF LFA-1 AND VLA-4 | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-114539121-A | A novel, photo-promoted process for the preparation of sulfonates and sulfonamides from sulfonyl chlorides | 天津师范大学 | 2022-05-27 | — | — | CN | disclosed |
| CN-105993088-A | Coated negative-electrode active material for use in lithium-ion battery, slurry for use in lithium-ion battery, negative electrode for use in lithium-ion battery, lithium-ion battery, and method for manufacturing coated negative-electrode active material for use in lithium-ion battery | 三洋化成工业株式会社 | 2016-10-05 | — | — | CN | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | ALDH1A1 1020/4885LMNA 1674/4885TSPO 1863/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | ALDH1A1 239/4885LMNA 2376/4885TSPO 2078/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | ALDH1A1 239/4885LMNA 2376/4885TSPO 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.